GoAI
Get started
BioVie Inc. logo

BioVie Inc.

BIVI

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$1.95

+$0.09 · +4.84%

Aug 21, 4:00 PM ET

BIVI company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

46

Fair Value

Momentum

74

Gaining

Sentiment

59

Mixed

Risk resilience

32

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry
Biotechnology
Sector
Healthcare
Headquarters
US

Market position

Day range

Current $1.95

52-week range

Current $1.95

Open
$2.24
Previous close
$1.86
Volume
19.76M
Market cap
14.71M USD
50-day average
$1.6626
+17.29% above average
200-day average
$1.4629
+33.29% above average

Financials

Financial statements

Income trends

Operating income

−22.65M USD-25.38%

Net income

−22.07M USD-25.83%
Income trends across reported periods−14.27M USD−27.36M USD−40.44M USD−53.53M USDOperating income, FY2022: −27.25M USDOperating income, FY2023: −45.08M USDOperating income, FY2024: −32.18M USDOperating income, FY2025: −18.07M USDOperating income, FY2026: −22.65M USDNet income, FY2022: −26.08M USDNet income, FY2023: −50.26M USDNet income, FY2024: −32.12M USDNet income, FY2025: −17.54M USDNet income, FY2026: −22.07M USDFY2022FY2023FY2024FY2025FY2026
Operating income FY2022 −27.25M USD. Operating income FY2023 −45.08M USD. Operating income FY2024 −32.18M USD. Operating income FY2025 −18.07M USD. Operating income FY2026 −22.65M USD. Net income FY2022 −26.08M USD. Net income FY2023 −50.26M USD. Net income FY2024 −32.12M USD. Net income FY2025 −17.54M USD. Net income FY2026 −22.07M USD.
Metric (USD)FY2026FY2025FY2024FY2023FY2022
Cost of goods sold—229.38K USD———
Gross profit—−229.38K USD———
Research and development13.96M USD9.27M USD23.1M USD33.3M USD17.26M USD
Selling, general, and administrative8.51M USD8.57M USD—11.55M USD—
Operating expenses22.65M USD17.84M USD32.18M USD45.08M USD27.25M USD
Interest income596.77K USD853.03K USD1.14M USD562.26K USD44.08K USD
Interest expense17.9K USD332.72K USD2.89M USD4.3M USD2.16M USD
Depreciation and amortization178.34K USD229.38K USD229.38K USD229.38K USD229.38K USD
Operating income−22.65M USD−18.07M USD−32.18M USD−45.08M USD−27.25M USD
Net income−22.07M USD−17.54M USD−32.12M USD−50.26M USD−26.08M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 3 misses, 2 met estimates
Average EPS surprise
-582.24%
11 comparable reports
Latest EPS result
-0.7
Estimate -0.52 · Miss by 34.62%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.44-6.04-11.64-17.24Q4 '24BeatQ1 '25BeatQ2 '25BeatQ3 '25MetQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26Miss
Q4 2024, reported Nov 13, 2024: actual -7, estimate -16, surprise +56.25%, Beat. Q1 2025, reported Feb 11, 2025: actual -4.6, estimate -16, surprise +71.25%, Beat. Q2 2025, reported May 12, 2025: actual -1.5, estimate -3.2, surprise +53.13%, Beat. Q3 2025, reported Aug 15, 2025: actual -1.82, estimate -1.82, surprise 0.00%, Met estimate. Q4 2025, reported Nov 10, 2025: actual -0.98, estimate -0.79, surprise -24.05%, Miss. Q1 2026, reported Feb 10, 2026: actual -0.77, estimate -0.81, surprise +4.94%, Beat. Q2 2026, reported May 11, 2026: actual -0.7, estimate -0.73, surprise +4.11%, Beat. Q3 2026, reported Aug 12, 2026: actual -0.7, estimate -0.52, surprise -34.62%, Miss.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

5 ratings
Strong buy00%
Buy5100%
Hold00%
Sell00%
Strong sell00%

BIVI news

seekingalpha.com

BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design Transcript

BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design Transcript

Read source
proactiveinvestors.com

Parkinson's drug developers are betting big on inflammation

For years, the hunt for a Parkinson's disease-modifying drug came down to one protein: alpha-synuclein. Clear it out, the thinking went, and you slow the disease.

Read source
proactiveinvestors.com

Vaalco Energy quarter sales jump, ups guidance

Vaalco Energy Inc (LSE:EGY) told investors that second-quarter sales jumped 47% from the previous three months as higher Gabon liftings and Egyptian volumes...

Read source
proactiveinvestors.com

Apple App Store revenue ticks up despite falling downloads

Apple Inc (NASDAQ:AAPL, XETRA:APC) App Store revenue rose 0.6% year-over-year in the first 35 days of its fiscal fourth quarter to $3.4 billion, up from...

Read source
proactiveinvestors.com

Uber price target lowered by Bank of America despite higher earnings outlook

Uber Technologies Inc (NYSE:UBER, XETRA:UT8) saw its price target lowered to $101 from $103 by Bank of America, which maintained a ‘Buy’ rating following...

Read source
proactiveinvestors.com

BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its drug candidate bezisterim met the prespecified endpoints of a Phase 2 trial in early-stage Parkinson's disease, with patients showing improvements in blood-based…

Read source

BIVI peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding BIVI

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
107.78K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research BIVI

research.disclaimer